EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 1188)

[toothstone]

Haben wohl die ersten ihre neuen Aktien vertickert.

[Cavemen]

Code Last $ +/- Bid Offer Open High Low Volume
PSD * 1.260 -0.080 1.260 1.270 1.350 1.350 1.250 1,046,590

[11eas]

22 Apr 2004 16:06 Delayed | Live Quote
Last Price +/- % Open High Volume
$1.2600 $-0.1000 -7.4% 1.3500 1.3500 1,046,590

[toothstone]

2 hoch 1 zurück:
momentan1,29 in Au
viel Spaß noch

[11eas]

ASX/MEDIA RELEASE 22 April 2004
Additional A$6.5M Placement to European Funds
PREMIUM TO RECENT RAISING
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce the placement of 5,625,000 fully paid ordinary shares at US$0.85 (A$1.16), raising A$6.5 million before costs.
The shares were placed with the Absolute Return Europe Fund (3,750,000) and European Catalyst Fund (1,875,000). Both funds are managed by European based FM Fund Management Ltd.
The placement is at a 6.5% premium to the recent A$21 million capital raising to US and European institutional investors at A$1.09 (US$0.80). pSivida’s overseas shareholder base will now increase to in excess of 40%.
The placement was in response to strong demand in Europe for additional stock from the previous placement. A total of A$27.5 million has now been raised and places the Company in a very strong financial position providing the ability to further develop the BioSiliconTM technology to a point where it anticipates the receipt of its first significant revenues.
FM Fund Management Ltd is a specialist asset manager with operations in Switzerland, Spain, Germany and the Americas. The firm’s lead manager and majority shareholder is Florian Homm, one of the most renowned European investors and a specialist in the Life Sciences sectors.
Mr. Homm has won several major investment awards from agencies such as Lipper, Micropal, S&P, Morningstar and Finanzen and as the founder and largest shareholder, he also developed Value Management and Research AG into one of the largest and most profitable independent asset managers in Germany with a peak stock market value of €550 million.
pSivida Managing Director, Mr. Gavin Rezos said, “We are pleased to have FM Fund Management Ltd as a shareholder and believe that they will add further value in enhancing the Company’s profile in Europe with institutional investors, respected European commentators and analysts in both the biotechnology and nanotechnology sectors.”
-ENDS-
Released by:
Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
[e-mail]

[11eas]

ASX/MEDIA RELEASE 22 April 2004
Additional A$6.5M Placement to European Funds
PREMIUM TO RECENT RAISING
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce the placement of 5,625,000 fully paid ordinary shares at US$0.85 (A$1.16), raising A$6.5 million before costs.
The shares were placed with the Absolute Return Europe Fund (3,750,000) and European Catalyst Fund (1,875,000). Both funds are managed by European based FM Fund Management Ltd.
The placement is at a 6.5% premium to the recent A$21 million capital raising to US and European institutional investors at A$1.09 (US$0.80). pSivida’s overseas shareholder base will now increase to in excess of 40%.
The placement was in response to strong demand in Europe for additional stock from the previous placement. A total of A$27.5 million has now been raised and places the Company in a very strong financial position providing the ability to further develop the BioSiliconTM technology to a point where it anticipates the receipt of its first significant revenues.
FM Fund Management Ltd is a specialist asset manager with operations in Switzerland, Spain, Germany and the Americas. The firm’s lead manager and majority shareholder is Florian Homm, one of the most renowned European investors and a specialist in the Life Sciences sectors.
Mr. Homm has won several major investment awards from agencies such as Lipper, Micropal, S&P, Morningstar and Finanzen and as the founder and largest shareholder, he also developed Value Management and Research AG into one of the largest and most profitable independent asset managers in Germany with a peak stock market value of €550 million.
pSivida Managing Director, Mr. Gavin Rezos said, “We are pleased to have FM Fund Management Ltd as a shareholder and believe that they will add further value in enhancing the Company’s profile in Europe with institutional investors, respected European commentators and analysts in both the biotechnology and nanotechnology sectors.”
-ENDS-
Released by:
Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
[e-mail]

[Cavemen]

Code Last $ +/- Bid Offer Open High Low Volume
PSD * 1.290 -0.050 1.270 1.250 1.350 1.350 1.250 1,022,560

[riskfreak]

sorry- aber Dein Kurs stimmt nicht! Umgerechnet sind es 0.83 cent. In Yahoo Finance gibt es einen Rechner!

[riskfreak]

sorry- gehört hier zwar nicht hin- aber nachdem doch einige hier auch in Arqule investiert sind: Die Amis haben hier einen super Ritt heute vollzogen! Von ca. 18 Uhr - 11% zum Schlusskurs + 0.6%. Das können wirklich nur die Amis!- und das macht die Börse dort auch so sympatisch!

[riskfreak]

o.k.- sorry! Wenn Du den Langfristchart meinst- hast natürlich schon recht!